Interferon Alpha-2a Treatment for Post-Uveitic Refractory Macular Edema

References

• Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm. 2003;11(1):29–38.
   Web of Science ®Google Scholar
• Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113:1446–1449. doi:10.1016/j.ophtha.2006.03.027.
   PubMed Web of Science ®Google Scholar
• Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm. 2002;10:239–246. doi:10.1076/ocii.10.4.239.15589.
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Lightman S, Drye L, et al. Outcome of treatment of uveitic macular edema: the multicenter uveitis steroid treatment trial 2-year results. Ophthalmology. 2015. doi:10.1016/j.ophtha.2015.07.036.
   Google Scholar
• Wardiana A, Ningrum RA. Roferon-A : a Biologic Product of Human Interferon Alpha 2a. Annales Bogorienses-Journal of Tropical General Botany 2015;19(2):1–11.
   Web of Science ®Google Scholar
• Kötter I, Zierhut M, Eckstein AK. et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–431. doi:10.1136/bjo.87.4.423.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C. et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146:837–844.e1. doi:10.1016/j.ajo.2008.08.038.
   PubMed Web of Science ®Google Scholar
• Diwo E, Gueudry J, Saadoun D, Weschler B, LeHoang P, Bodaghi B. Long-term efficacy of interferon in severe uveitis associated with Behçet disease. Ocul Immunol Inflamm. 2017;25(1):76–84. doi:10.1080/09273948.2016.1206204.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Koetter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26:786–791. doi:10.1097/01.iae.0000244265.75771.71.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Kötter I, Günaydin I, Stübiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906–913. doi:10.1136/bjo.2008.153874.
   PubMed Web of Science ®Google Scholar
• Deuter C, Stubiger N, Zierhut M. Interferon-alpha therapy in noninfectious uveitis. Dev Ophthalmol. 2012. doi:10.1159/000336324.
   PubMedGoogle Scholar
• Oray M, Onal S, Uludag G, Akbay AK, Tugal-Tutkun I. Interferon alpha for the treatment of cystoid macular edema associated with presumed ocular tuberculosis. J Ocul Pharmacol Ther. 2017;33:304–312. doi:10.1089/jop.2016.0097.
   PubMed Web of Science ®Google Scholar
• Invernizzi A, Iannaccone F, Marchi S, et al. Interferon alpha-2a for the treatment of post-infectious uveitis secondary to presumed intraocular tuberculosis. Ocul Immunol Inflamm. February 2018;1–8. doi:10.1080/09273948.2018.1431292.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Interferon-Alpha ST. 2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res. 1995;49:277–288. doi:10.1006/mvre.1995.1024.
   PubMed Web of Science ®Google Scholar
• Huizinga T, Knevel R. Rheumatoid arthritis: 2014 treat-to-target RA recommendations - strategy is key. Nat Rev Rheumatol. 2015;49:277–288. doi:10.1038/nrrheum.2015.98.
   Google Scholar
• Gupta V, Gupta A, Rao NA. Intraocular tuberculosis–an update. Surv Ophthalmol. 2007;52(6):561–587. doi:10.1016/j.survophthal.2007.08.015.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Gunasekeran DV, Grant R, et al. Collaborative Ocular Tuberculosis Study (COTS)–1 study group. Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the collaborative ocular tuberculosis study (COTS)-1. JAMA Ophthalmol. 2017 Dec 1;135(12):1318–1327. doi:10.1001/jamaophthalmol.2017.4485.
   PubMed Web of Science ®Google Scholar
• Doycheva D, Deuter C, Stuebiger N, Zierhut M. Interferon-alpha-associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):675–680. doi:10.1007/s00417-008-1002-5.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005. doi:10.1016/j.ajo.2005.03.057.
   Web of Science ®Google Scholar
• Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biol Targets Ther. 2014. doi:10.2147/BTT.S41477.
   PubMedGoogle Scholar
• Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2014;13:54–58. doi:10.1016/j.autrev.2013.09.002.
   PubMed Web of Science ®Google Scholar
• Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep. 2017;17. doi:10.1007/s11910-017-0742-1.
   PubMed Web of Science ®Google Scholar
• Quesada J, Psoriasis GJ. Alpha-interferon. Lancet. 1986;327(8496):1466–1468. doi:10.1016/S0140-6736(86)91502-3.
   Google Scholar
• Preziati D, La Rosa L, Covini G. et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol. 1995;132:587–593. doi:10.1530/eje.0.1320587.
   PubMed Web of Science ®Google Scholar
• Guyer DR, Tiedeman J, Yannuzzi LA. et al. Interferon-associated retinopathy. Arch Ophthalmol. 1993;111:350. doi:10.1001/archopht.1993.01090030068041.
   PubMed Web of Science ®Google Scholar
• Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol. 1995;113:1041. doi:10.1001/archopht.1995.01100080093034.
   PubMed Web of Science ®Google Scholar